Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
34 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Acurx Pharmaceuticals, Inc.’s names, not what it holds today.
Patents granted
34
34 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against 2 in 2024 and 2 in 2023
Applications published
45
since 2001, to Dec 31, 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'09'10'11'12'13'14'15'16'17'18'20'21'22'23'24
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Acurx Pharmaceuticals, Inc. its own name
US, as the owner printed on each patent
38 publishedAcurx Pharmaceuticals, LLC its own name
named as the applicant on its applications, in US
7 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Jul 16, 2024 | 12,036,225 | Use of ibezapolstat to promote microbiome health | Pharmaceuticals | Acurx Pharmaceuticals, Inc. |
| Jan 2, 2024 | 11,857,629 | Methods and compositions for self-regulated release of active pharmaceutical ingredient | Pharmaceuticals | Acurx Pharmaceuticals, Inc. |
| Aug 15, 2023 | 11,723,885 | Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse | Pharmaceuticals | Acurx Pharmaceuticals, Inc. |
| Jan 17, 2023 | 11,554,114 | Methods and compositions for self-regulated release of active pharmaceutical ingredients | Pharmaceuticals | Acurx Pharmaceuticals, Inc. |
| Dec 14, 2021 | 11,197,837 | Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse | Pharmaceuticals | Acurx Pharmaceuticals, Inc. |
| Aug 31, 2021 | 11,103,581 | Methods and compositions for self-regulated release of active pharmaceutical ingredient | Pharmaceuticals | Acurx Pharmaceuticals, Inc. |
| Aug 10, 2021 | 11,083,794 | Methods and compositions for self-regulated release of active pharmaceutical ingredient | Pharmaceuticals | Acurx Pharmaceuticals, Inc. |
| May 11, 2021 | 11,001,592 | DNA polymerase IIIC inhibitors and use thereof | Pharmaceuticals | Acurx Pharmaceuticals, Inc. |
| Nov 17, 2020 | 10,836,772 | DNA polymerase IIIC inhibitors and use thereof | Pharmaceuticals | Acurx Pharmaceuticals, Inc. |
| Jul 28, 2020 | 10,723,741 | DNA polymerase IIIC inhibitors and use thereof | Pharmaceuticals | Acurx Pharmaceuticals, Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Sep 26, 2024 | 2024/0316058 | Use of Ibezapolstat to Promote Microbiome Health | Pharmaceuticals | Acurx Pharmaceuticals, LLC |
| Apr 4, 2024 | 2024/0108726 | METHODS AND COMPOSITIONS FOR SELF-REGULATED RELEASE OF ACTIVE PHARMACEUTICAL INGREDIENT | Pharmaceuticals | Acurx Pharmaceuticals, Inc. |
| Aug 10, 2023 | 2023/0250102 | DNA Polymerase IIIC Inhibitors and Use Thereof | Pharmaceuticals | Acurx Pharmaceuticals, LLC |
| Dec 29, 2022 | 2022/0409625 | Use of Ibezapolstat to Promote Microbiome Health | Pharmaceuticals | Acurx Pharmaceuticals, LLC · patent 12,036,225 granted from it |
| Apr 14, 2022 | 2022/0112195 | DNA Polymerase IIIC Inhibitors and Use Thereof | Pharmaceuticals | Acurx Pharmaceuticals, LLC |
| Mar 3, 2022 | 2022/0062202 | METHODS AND COMPOSITIONS FOR INTERFERING WITH EXTRACTION OR CONVERSION OF A DRUG SUSCEPTIBLE TO ABUSE | Pharmaceuticals | Acurx Pharmaceuticals, Inc. · patent 11,723,885 granted from it |
| Jan 27, 2022 | 2022/0024925 | Deuterium-Substituted 7-Substituted-2-(Benzylamino)-6-Ozopurine Compounds and Uses Thereof | Organic fine chemistry | Acurx Pharmaceuticals, LLC |
| Oct 28, 2021 | 2021/0330793 | METHODS AND COMPOSITIONS FOR SELF-REGULATED RELEASE OF ACTIVE PHARMACEUTICAL INGREDIENT | Pharmaceuticals | Acurx Pharmaceuticals, Inc. · patent 11,857,629 granted from it |
| Apr 22, 2021 | 2021/0113542 | METHODS AND COMPOSITIONS FOR SELF-REGULATED RELEASE OF ACTIVE PHARMACEUTICAL INGREDIENTS | Pharmaceuticals | Acurx Pharmaceuticals, Inc. · patent 11,554,114 granted from it |
| Mar 18, 2021 | 2021/0077484 | ABUSE DETERRENT COMPOSITIONS AND METHODS OF MAKING SAME | Pharmaceuticals | Acurx Pharmaceuticals, Inc. |
What it applied for, 2024 to 2025: Pharmaceuticals 2.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.